Invesco’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

Invesco’s Portfolio SYRS Stock Details SYRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-1,911	Closed	-$23K	–	4167
2022 Q1	$23K	Buy	1,911 +9	+0.5%	+$161	﹤0.01%	3984
2021 Q4	$62K	Sell	1,902 -282	-13%	-$11.4K	﹤0.01%	3956
2021 Q3	$97K	Buy	2,184 +363	+20%	+$17.7K	﹤0.01%	3945
2021 Q2	$99K	Buy	1,821 +703	+63%	+$41.6K	﹤0.01%	3894
2021 Q1	$84K	Buy	+1,118	New	+$116K	﹤0.01%	3780
2020 Q2	–	Sell	-9,001	Closed	-$534K	–	3699
2020 Q1	$534K	Buy	+9,001	New	+$611K	﹤0.01%	3024
2019 Q4	–	Sell	-7,721	Closed	-$801K	–	3714
2019 Q3	$801K	Buy	+7,721	New	+$729K	﹤0.01%	3093

Other funds holding SYRS

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

ABG

Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Invesco's SYRS Position: Q2 2022 in Review

Invesco sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q2 2022, closing a stake of 1,911 shares — an estimated $23K sold.

Invesco first reported a position in SYRS in Q3 2019 and held it in 7 quarters. The position peaked at $801K in Q3 2019. 67 funds tracked by Wall St. Rank hold SYRS as of Q2 2022.

Invesco reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
Invesco sold 1,911 Syros Pharmaceuticals, Inc. Common Stock shares in Q2 2022, an estimated $23K.
Invesco first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q3 2019 and held it in 7 quarters.
Invesco's Syros Pharmaceuticals, Inc. Common Stock position peaked at $801K in Q3 2019.
67 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q2 2022.

Based on Invesco's 13F filing for Q2 2022, filed 15 Aug 2022.